Brukinsa is an anti-cancer drug owned by Beigene, which was authorized for market use on 14th November 2019. The drug contains an active ingredient, zanubrutinib, used for treatment of various types of lymphoma conditions.
Being a relatively new drug on the market, the patents for Brukinsa are all active. While the generics could be possible to be released after 19th January 2043, that is after the expiration of the last patent, the first possible challenge against the drug’s patents could occur from 15th November 2023.
Brukinsa, with its active ingredient zanubrutinib, is primarily used in the treatment of patients with different conditions such as Waldenstrom's macroglobulinemia, mantle cell lymphoma, and chronic lymphocytic leukemia or small lymphocytic lymphoma. It is effectively used in cases where patients have received at least one prior therapy. The drug can also be used alongside a moderate CYP3A inducer.
The drug Brukinsa is protected by six patents with none having expired yet. The patents relate to various aspects of the drug such as methods of treatment of B-cell proliferative disorder and bruton's tyrosine kinase modulators. The date of expiration for the last patent is 19th January 2043. The details of the patents are listed below: